MSD Japan
Manufacturing · Japan · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Kitanomaru Square 1-13-12 Kudankita, Chi...Phone Number
+81 362721000Website
www.msd.co.jpRevenue
$578.4 MillionIndustry
About MSD Japan
MSD Japan Org Chart
Is MSD Japan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MSD Japan has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on MSD Japan recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MSD Japan, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MSD Japan has new funding data
Congratulate Masked Content for being promoted to Masked Content at MSD Japan
Check out if MSD Japan is spiking on competitors!
Product Launch: Get notified when MSD Japan launches new products
Click to see if MSD Japan had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined MSD Japan as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
MSD Japan is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MSD Japan is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MSD Japan.
MSD Japan Tech Stack
A closer look at the technologies used by MSD Japan
Most Recent Scoops
MSD Japan News & Media
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today an application submission in Japan for the additional indication of Eisai's in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA (generic name: lenvatinib mesylate), in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s KEYTRUDA (generic name: pembrolizuma
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MSD Japan
MSD, a subsidiary of Merck & Co. Inc, is a biopharmaceutical company developing new drugs that meet the medical needs of Japan and producing medicines. The company is based in Tokyo, Japan.... Read More